Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -92.20% is 41% below its 2-year average of -65.45%, near the low end of its 2-year range (-122.75%–-13.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.31% below its 12-month average of -86.73%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -92.20%.
RETURN ON EQUITY (ROE)
-92.20%
RETURN ON EQUITY (ROE) AVG TTM
-86.73%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.31%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-119.47%
vs the sector median at left
Kyverna Therapeutics, Inc.
Market Cap
$374.50M
Return on Equity (ROE)
-92.20%
TTM Avg
-86.73%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$376.01M
Return on Equity (ROE)
-38.57%
TTM Avg
-80.22%
3Y Avg
-181.01%
5Y Avg
-130.47%
Market Cap
$376.19M
Return on Equity (ROE)
-43.51%
TTM Avg
-51.65%
3Y Avg
-31.19%
5Y Avg
-23.66%
Market Cap
$369.50M
Return on Equity (ROE)
-54.29%
TTM Avg
-32.16%
3Y Avg
-17.89%
5Y Avg
-29.83%
Market Cap
$380.37M
Return on Equity (ROE)
-14.38%
TTM Avg
-22.77%
3Y Avg
-19.17%
5Y Avg
-14.56%
Market Cap
$385.15M
Return on Equity (ROE)
-273.72%
TTM Avg
-138.09%
3Y Avg
-103.75%
5Y Avg
-71.29%
Market Cap
$361.64M
Return on Equity (ROE)
N/A
TTM Avg
-589.37%
3Y Avg
-290.01%
5Y Avg
-205.39%
Market Cap
$359.53M
Return on Equity (ROE)
-7.66%
TTM Avg
-10.18%
3Y Avg
260.20%
5Y Avg
144.75%
Market Cap
$355.43M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $374.50M | -92.20% | -86.73% | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.01M | -38.57% | -80.22% | -181.01% | -130.47% |
| Zura Bio Limited (ZURA)vs › | $376.19M | -43.51% | -51.65% | -31.19% | -23.66% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | -54.29% | -32.16% | -17.89% | -29.83% |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | -14.38% | -22.77% | -19.17% | -14.56% |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | -273.72% | -138.09% | -103.75% | -71.29% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -589.37% | -290.01% | -205.39% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -7.66% | -10.18% | 260.20% | 144.75% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -26.14% | -53.80% | -12.25% | 19.21% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 10.07% | 9.56% | 8.63% | 13.79% |
ROE
-92.2%
ROA
-69.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -92.20% |
| 2026-03-31 | -79.97% |
| 2025-12-31 | -69.45% |
| 2025-09-30 | -105.95% |
| 2025-06-30 | -86.07% |
| 2025-03-31 | -64.92% |
| 2024-12-31 | -37.82% |
| 2024-09-30 | -27.75% |
| 2024-06-30 | -19.48% |
| 2024-03-31 | -13.64% |
| 2023-12-31 | -122.75% |
